Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children's Cancer Group and Pediatric Oncology Branch study

Blood

Volumn 92, Issue 10, 1998, Pages 3569-3577

  Balis, Frank M ^a   Holcenberg, John S ^b   Poplack, David G ^b   Ge, Jeffrey ^b   Sather, Harland N ^b   Murphy, Robert F ^b   Ames, Matthew M ^b   Waskerwitz, Mary J ^b   Tubergen, David G ^b   Zimm, Solomon ^b   Gilchrist, Gerald S ^b   Archie Bleyer, W ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; THIOGUANINE DERIVATIVE; THIOGUANOSINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; ERYTHROCYTE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032533637     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.10.3569     Document Type: Article

References (25)

1. Balis FM, Savitch JL, Bleyer WA: Pharmacokinetics of oral methotrexate in children. Cancer Res 43:2342, 1983
2. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG: Variable bioavailability of oral mercaptopurine. N Engl J Med 308:1005, 1983
3. Kearney PJ, Light PA, Preece A, Mott MG: Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 3:117, 1979
4. Pinkerton CR, Welshman SG, Kelly JG, Shanks RG, Bridges JM: Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 10:36, 1982
5. Pinkerton CR, Welshman SG, Bridges JM: Serum profiles of methotrexate after its administration in children with acute lymphoblastic leukaemia. Br J Cancer 45:300, 1982
6. Balis FM, Mirro J, Reaman GH, Evans WE, McCully C, Doherty KM, Murphy RF, Jeffries S, Poplack DG: Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 6:1882, 1988
7. Campbell MA, Perrier DG, Dorr RT, Alberts DS, Finley PR: Methotrexate: Bioavailability and pharmacokinetics. Cancer Treat Rep 69:833, 1985
8. Smith DK, Omura GA, Ostroy F: Clinical pharmacology of intermediate-dose oral methotrexate. Cancer Chemother Pharmacol 4:117, 1980
9. Lennard L, Keen D, Lilleyman JS: Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin Pharmacol Ther 40:287, 1986
10. Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M: Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. Clin Pharmacol Ther 40:604, 1986
11. Poplack DG, Balis FM, Zimm S: The pharmacology of orally administered chemotherapy, Cancer 58:473, 1986 (suppl)
12. Pearson AD, Amineddine HA, Yule M, Mills S, Long DR, Craft AW, Chessells JM: The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia. Br J Cancer 64:169, 1991
13. Koren G, Ferrazini G, Sulh H, Langevin AM, Kapelushnik J, Klein J, Giesbrecht E, Soldin S, Greenberg M: Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children. N Engl J Med 323:17, 1990
14. Schmiegelow K, Schrøder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T, Wranne L: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 13:345, 1995
15. Lennard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816, 1989
16. Lennard L, Rees CA, Lilleyman JS, Maddocks JL: Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359, 1983
17. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukemia. Lancet 343:1188, 1994
18. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527, 1993
19. Lange BJ, Blatt J, Sather HN, Meadows AT: Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: A Childrens Cancer Group Study. Med Pediatr Oncol 27:15, 1996
20. Falk LC, Clark DR, Kalman SM, Long TF: Enzymatic assay for methotrexate in serum and cerebrospinal fluid. Clin Chem 22:785, 1976
21. Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, Cogliano-Shutta N, Balis F, Lavi LE, Collins JM, Poplack DG: Phase I and clinical pharmacologic study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45:1869, 1985
22. Lavi LE, Holcenberg JS: A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem 144:514, 1985
23. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Marcel Dekker, 1982
24. Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, Hammond D, Poplack DG: The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 41:384, 1987
25. Davies HA, Leonard L, Lilleyman JS: Variable mercaptopurine metabolism in children with leukæmia: A problem of compliance? Br Med J 306:1239, 1993